A clinical trial that followed more than 9,900 people in 24 countries has found that the drug dulaglutide reduced cardiovascular events and kidney problems in middle-aged and older people with Type 2 diabetes.
Chukwuma Muanya
The News You Need, Delivered To You.
Subscribe to the Guardian today and never miss the stories that shape your Business